The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

The FDA has approved semaglutide for treating MASH, a significant advancement in liver disease management. Semaglutide, ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

The condition starts off as non-alcoholic, or as it is now known metabolic-associated, fatty liver disease. This fat build-up ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Originally established by Robert Cooke in East London, F. Cooke is the oldest established eel and pie house family still in ...

An average serving of instant mash provides 46mg of vitamin C - three-quarters of the recommended daily allowance. But whether mash is healthier than chips or not is all in the serving.